Enviroxime | CAS#72301-79-2 | Antiviral

Enviroxime
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319912

CAS#: 72301-79-2

Description: Enviroxime, also known as LY 122772 and NSC 346230, is an anti-Infective and antiviral agent. Enviroxime targets the 3A coding region of rhinovirus and poliovirus. Combining enviroxime with disoxaril resulted in synergistic interaction.

Chemical Structure

Enviroxime

CAS# 72301-79-2

Instruction

Theoretical Analysis

MedKoo Cat#: 319912
Name: Enviroxime
CAS#: 72301-79-2
Chemical Formula: C17H18N4O3S
Exact Mass: 358.11
Molecular Weight: 358.416
Elemental Analysis: C, 56.97; H, 5.06; N, 15.63; O, 13.39; S, 8.94

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: LY-122772; LY122772; LY 122772; LY122771-72; NSC 346230; Enviroxime; Viroxime component B; Enviroxima.

IUPAC/Chemical Name: (E)-2-Amino-6-benzoyl-1-(isopropylsulfonyl)benzimidazole oxime

InChi Key: IWKXBHQELWQLHF-CAPFRKAQSA-N

InChi Code: InChI=1S/C17H18N4O3S/c1-11(2)25(23,24)21-15-10-13(8-9-14(15)19-17(21)18)16(20-22)12-6-4-3-5-7-12/h3-11,22H,1-2H3,(H2,18,19)/b20-16+

SMILES Code: O=S(N1C2=CC(/C(C3=CC=CC=C3)=N/O)=CC=C2N=C1N)(C(C)C)=O

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 358.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Levandowski RA, Pachucki CT, Rubenis M, Jackson GG. Topical enviroxime against rhinovirus infection. Antimicrob Agents Chemother. 1982 Dec;22(6):1004-7. doi: 10.1128/AAC.22.6.1004. PMID: 6297380; PMCID: PMC185710.

2: Brown-Augsburger P, Vance LM, Malcolm SK, Hsiung H, Smith DP, Heinz BA. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch Virol. 1999;144(8):1569-85. doi: 10.1007/s007050050611. PMID: 10486111.

3: Delang L, Harak C, Benkheil M, Khan H, Leyssen P, Andrews M, Lohmann V, Neyts J. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases. J Antimicrob Chemother. 2018 Dec 1;73(12):3375-3384. doi: 10.1093/jac/dky327. PMID: 30219827.

4: Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol. 2013 Apr;87(8):4252-60. doi: 10.1128/JVI.03546-12. Epub 2013 Jan 30. PMID: 23365445; PMCID: PMC3624399.

5: Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995 Jul;69(7):4189-97. doi: 10.1128/JVI.69.7.4189-4197.1995. PMID: 7769678; PMCID: PMC189156.

6: Wyde PR, Six HR, Wilson SZ, Gilbert BE, Knight V. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother. 1988 Jun;32(6):890-5. doi: 10.1128/AAC.32.6.890. PMID: 2843086; PMCID: PMC172302.

7: Phillpotts RJ, Wallace J, Tyrrell DA, Tagart VB. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother. 1983 May;23(5):671-5. doi: 10.1128/AAC.23.5.671. PMID: 6870216; PMCID: PMC184785.

8: Hayden FG, Gwaltney JM Jr. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother. 1982 Jun;21(6):892-7. doi: 10.1128/AAC.21.6.892. PMID: 6287928; PMCID: PMC182041.

9: Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol. 2011 Mar;85(5):2364-72. doi: 10.1128/JVI.02249-10. Epub 2010 Dec 22. PMID: 21177810; PMCID: PMC3067798.

10: Phillpotts RJ, Jones RW, Delong DC, Reed SE, Wallace J, Tyrrell DA. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981 Jun 20;1(8234):1342-4. doi: 10.1016/s0140-6736(81)92520-4. PMID: 6113314.

11: Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER, Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother. 1985 Jan;27(1):102-6. doi: 10.1128/AAC.27.1.102. PMID: 2984980; PMCID: PMC176213.

12: Phillpotts RJ, Tyrrell DA. Rhinovirus colds. Br Med Bull. 1985 Oct;41(4):386-90. doi: 10.1093/oxfordjournals.bmb.a072081. PMID: 2996687.

13: Nikolaeva L, Galabov AS. Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication. Acta Virol. 1995 Dec;39(5-6):235-41. PMID: 8722291.

14: Victor F, Brown TJ, Campanale K, Heinz BA, Shipley LA, Su KS, Tang J, Vance LM, Spitzer WA. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. J Med Chem. 1997 May 9;40(10):1511-8. doi: 10.1021/jm960718i. PMID: 9154972.

15: Higgins PG, Barrow GI, al-Nakib W, Tyrrell DA, DeLong DC, Lenox-Smith I. Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers. Antiviral Res. 1988 Nov;10(1-3):141-9. doi: 10.1016/0166-3542(88)90022-8. PMID: 3232968.

16: Gilbert BE, Six HR, Wilson SZ, Wyde PR, Knight V. Small particle aerosols of enviroxime-containing liposomes. Antiviral Res. 1988 Sep;9(6):355-65. doi: 10.1016/0166-3542(88)90037-x. PMID: 3228281.

17: Nikolaeva L, Galabov AS. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection. Acta Virol. 2000 Apr;44(2):73-8. PMID: 10989697.

18: Heinz BA, Vance LM. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J Virol. 1996 Jul;70(7):4854-7. doi: 10.1128/JVI.70.7.4854-4857.1996. PMID: 8676522; PMCID: PMC190432.

19: Ninomiya Y, Aoyama M, Umeda I, Suhara Y, Ishitsuka H. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime. Antimicrob Agents Chemother. 1985 Apr;27(4):595-9. doi: 10.1128/AAC.27.4.595. PMID: 2988431; PMCID: PMC180102.

20: Arita M. [Exploration for anti-enterovirus compounds and analysis on the mechanism of its inhibitory effect on virus infection]. Uirusu. 2013;63(1):93-102. Japanese. doi: 10.2222/jsv.63.93. PMID: 24769585.

Your view history

Enviroxime featured